National Institutes of Health logo

Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research

National Institutes of Health

Funding Amount

$5,200,000 total

Deadline

Forecast — dates not yet posted

Number of Awards

8

Grant Type

Federal

Can we apply?

Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.

Eligible organizations

  • For-profit businesses
  • Public colleges & universities
  • Small businesses
  • State governments
  • Tribal organizations
  • Special district governments
  • Public & Indian housing authorities
  • Nonprofits (501(c)(3))

Geography

  • Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Overview

The main goal of this initiative is to establish a consortium with the overarching goal to advance the systematic identification, rigorous evaluation, validation, and assays harmonization of biomarkers that are critical to the prevention, diagnosis, and clinical management of Type 1 Diabetes (T1D). Despite significant advances in T1D research, there remains an urgent need for reliable and reproducible biomarkers that can capture the complexity of autoimmune processes, metabolic dysregulation, and individual patient variability. This initiative will leverage state-of-the-art methodologies in clinical chemistry, genomics, proteomics, metabolomics, immunophenotyping, and imaging, coupled with longitudinal patient cohorts and mining of Electronic Health Records (EHR). Within this consortium major efforts will be devoted to: 1) Harmonize established assays for biomarkers such as HbA1c and c-peptide, making sure that these assays are performed in a rigorous and reproducible manner in the clinical research community and in clinical practice. For this purpose, reference methods and materials will use a metrology approach and will be made available to the community; 2) Identify and validate other biomarkers that can be used for the prevention, diagnosis, and clinical management of T1D. It has been reported that the assays for several biomarkers routinely used in clinical research such as glucagon, amylin, chromogranin, insulin, pro-insulin and other pro-hormones are not reproducible across platforms or laboratories. For this purpose, this consortium will ensure that all assays for biomarkers routinely used in clinical research and for newly identified biomarkers are rigorously validated and assessed for reproducibility across several laboratories following a metrology approach.

Details

  • Agency: National Institutes of Health
  • Department: Department of Health and Human Services
  • Opportunity #: RFA-DK-27-140
  • Total Funding: $5,200,000
  • Expected Awards: 8
  • Instrument: grant

Eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Focus Areas & Funding Uses

Fields of Work

  • Science research

Categories

Browse similar grants by category

Related Grants

Open grants from this funder and similar programs

Your AI grants department

Ready to apply for Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research?

Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.

You found Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research. Now let's win it.

Start writing